reports
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences: TD Cowen 46th Annual Health Care Conference: Fireside chat on Wednesday, March 4, 2026, at 1:10 p.m. ET in Boston, MA.2026 Jefferies Biotech on the Beach Summit: Company management will host 1x1 meetings on Tuesday, March 10, 2026, in Miam...
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Procee...
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,122,652 shares of common stock of the Company at an exercise price of $3.90 per share. The issuance or resale of the shares of common stock issuable upon exercise of the outstanding warrants has been registered pursuant...
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life ...
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, taking place virtually from February 25-26, 2026. Management, including Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer, will discuss the company’s pipeline, platform, and ...
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=3...
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on track for Q1 2026 milestone with unblinding thereafter; treated 35 subjects to date with another 11 identified Continued absence of cardiotoxicity and high efficacy expected to position Annamycin as a “significant advancement” in AML treatment HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MB...
Moleculin Announces Notice of Allowance for Japanese Patent Covering A...
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin HOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of allowance for Patent Application No. 2021-577862 titled, “METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN.” A patent from the application is expected to be issued in the coming months. The allowed claims cover proprietary methods for reconstituting and preparing liposomal Annamycin from a preliposomal lyophilizate under control...
Moleculin Launches CEO Corner Platform to Share Strategic Insights
Moleculin Launches CEO Corner Platform to Share Strategic Insights CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company by submitting questions and topics for future videos Access the Moleculin CEO Corner HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the launch of its CEO Corner, a new platform featuring Walter Klemp, Chief Executive Officer. The CEO Corner...
Moleculin to Participate in the Corporate Connect Webinar Series Virtu...
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial – on Wednesday, February 11th at 1:20 PM EST HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it will participate in the being held virtually February 10-11, 2026. Details of the presentation are as follows: Date and Time: Wednesday, February 11, 2026 at 1:20 PM ESTPresenter: Registration Link: About Webull Financial Webull Financial is a leading online brokerage platform committed to...
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
SCL STEPAN COMPANY
RLI RLI CORP.
NBTB NBT BANCORP INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LMNR LIMONEIRA CO.
IPAR INTER PARFUMS INC.
IP INTERNATIONAL PAPER COMPANY
INTC INTEL CORPORATION
GME GAMESTOP CORP. CLASS A
CMC COMMERCIAL METALS COMPANY
CGNX COGNEX CORPORATION
CASY CASEY'S GENERAL STORES INC.
CALX CALIX NETWORKS
PAR PAR TECHNOLOGY CORP.
PLBC PLUMAS BANCORP
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
CRVS CORVUS PHARMACEUTICALS
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
ESQ ESQUIRE FINANCIAL HOLDINGS
ABT ABBOTT LABORATORIES
THM INTERNATIONAL TOWER HILL MINES LTD
NWFL NORWOOD FINANCIAL CORP.
ZIVO ZIVO BIOSCIENCE
ANIX INC.
AMTB ANIXA BIOSCIENCES
CABA AMERANT BANCORP (A)
JYNT CABALETTA BIO
ALLY THE JOINT
ALT GMAC LLC
APG ALTIMMUNE INC
ZNTL API GROUP CORP
AVO ZENTALIS PHARMACEUTICALS
TMC MISSION PRODUCE
IMRX TMC THE METALS CO INC
BST IMMUNEERING CORP
LUCY BLACKROCK SCIENCE AND TECHNOLOGY TRUST
PMCB INNOVATIVE EYEWEAR INC
VANI PHARMACYTE BIOTECH INC
ACRV VIVANI MEDICAL INC
BOF ACRIVON THERAPEUTICS INC
SRBK BRANCHOUT FOOD INC.
WS WI SR BANCORP INC
GDV WORTHINGTON STEEL
GF THE GABELLI DIVIDEND & INCOME TRUST
CVM THE NEW GERMANY FUND
MSTR INC.
BDSX CEL-SCI CORPORATION
MPTI MICROSTRATEGY INCORPORATED
MIGI BIODESIX INC
SQNS M-TRON INDUSTRIES
INC.
MAWSON INFRASTRUCTURE GROUP INC
SEQUANS COMMUNICATIONS
- Jonathan Moreland
SCL STEPAN COMPANY
RLI RLI CORP.
LTC LTC PROPERTIES INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LMNR LIMONEIRA CO.
IPAR INTER PARFUMS INC.
GME GAMESTOP CORP. CLASS A
DAKT DAKTRONICS INC.
CMC COMMERCIAL METALS COMPANY
CGNX COGNEX CORPORATION
CASY CASEY'S GENERAL STORES INC.
CALX CALIX NETWORKS
WHF WHITEFIELD
ADC AGREE REALTY CORPORATION
PAR PAR TECHNOLOGY CORP.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
PLBC PLUMAS BANCORP
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
CLPR CLIPPER REALTY
BOMN BOSTON OMAHA
UA UNDER ARMOUR
NKE INC.
ESQ NIKE INC. CLASS B
FGBI ESQUIRE FINANCIAL HOLDINGS
GRX FIRST GUARANTY BANCSHARES
CABA THE GABELLI HEALTHCARE & WELLNESSRX TRUST
JYNT CABALETTA BIO
ALLY THE JOINT
ALT GMAC LLC
APG ALTIMMUNE INC
ZNTL API GROUP CORP
AVO ZENTALIS PHARMACEUTICALS
IVFH MISSION PRODUCE
TMC INNOVATIVE FOOD HLDG
IMRX TMC THE METALS CO INC
LUCY IMMUNEERING CORP
PMCB INNOVATIVE EYEWEAR INC
GLSI PHARMACYTE BIOTECH INC
VANI GREENWICH LIFESCIENCES INC
ACRV VIVANI MEDICAL INC
SUNS ACRIVON THERAPEUTICS INC
GF SUNRISE REALTY TRUST
MSTR THE NEW GERMANY FUND
MPTI INC.
MIGI MICROSTRATEGY INCORPORATED
SQNS M-TRON INDUSTRIES
INC.
MAWSON INFRASTRUCTURE GROUP INC
SEQUANS COMMUNICATIONS
- Jonathan Moreland
- Jonathan Moreland
- Jonathan Moreland
SCL STEPAN COMPANY
MOD MODINE MANUFACTURING COMPANY
LTC LTC PROPERTIES INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LMNR LIMONEIRA CO.
DAKT DAKTRONICS INC.
CGNX COGNEX CORPORATION
CASY CASEY'S GENERAL STORES INC.
CALX CALIX NETWORKS
WHF WHITEFIELD
ADC AGREE REALTY CORPORATION
PAR PAR TECHNOLOGY CORP.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
PLBC PLUMAS BANCORP
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
CLPR CLIPPER REALTY
BOMN BOSTON OMAHA
UA UNDER ARMOUR
NKE INC.
ESQ NIKE INC. CLASS B
FGBI ESQUIRE FINANCIAL HOLDINGS
GRX FIRST GUARANTY BANCSHARES
JYNT THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ALT THE JOINT
APG ALTIMMUNE INC
ZNTL API GROUP CORP
IVFH ZENTALIS PHARMACEUTICALS
TMC INNOVATIVE FOOD HLDG
IMRX TMC THE METALS CO INC
WRB IMMUNEERING CORP
LUCY W.R. BERKLEY CORPORATION
PMCB INNOVATIVE EYEWEAR INC
GLSI PHARMACYTE BIOTECH INC
MAIA GREENWICH LIFESCIENCES INC
ACRV MAIA BIOTECHNOLOGY INC
SUNS ACRIVON THERAPEUTICS INC
GF SUNRISE REALTY TRUST
MSTR THE NEW GERMANY FUND
MPTI INC.
SQNS MICROSTRATEGY INCORPORATED
MIGI M-TRON INDUSTRIES
INC.
SEQUANS COMMUNICATIONS
MAWSON INFRASTRUCTURE GROUP INC
Thor Industries Inc: 1 director
A director at Thor Industries Inc sold 4,567 shares at 114.845USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
- Jonathan Moreland
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of...
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects – Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating multiple oncology indications HOUSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), announced it has received a new independent assessment for the absence of cardiotoxicity in subjects treated with Annamycin, bringing the total number of An...
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unbli...
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs – First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today provided a business outlo...
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in...
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 cli...
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Confer...
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:00 a.m. PT (12:00 p.m. ET) in San Francisco, California. A live audio webcast of the presentation will be av...
- Jonathan Moreland
WHF WHITEHORSE FINANCE INC.
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
CUBE CUBESMART
CE CELANESE CORPORATION
AZO AUTOZONE INC.
ALG ALAMO GROUP INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
NB NIOCORP DEVELOPMENTS LTD
OXM OXFORD INDUSTRIES INC.
AP AMPCO-PITTSBURGH
WMG WARNER MUSIC GROUP CORP.
NKE NIKE INC. CLASS B
ELAN ELANCO ANIMAL HEALTH INC.
AMCR AMCOR PLC
ENR EDGEWELL PERSONAL CARE COMPANY
SELF SELF STORAGE GROUP
DHC INC.
COO DIVERSIFIED HEALTHCARE TRUST
RZLT THE COOPER COMPANIES INC.
AZYO REZOLUTE
IMNM INC.
ACVA AZIYO BIOLOGICS
BMEA IMMUNOME
PBBK ACV AUCTIONS INC.
OWL BIOMEA FUSION
IMMX INC.
NUVL PB BANKSHARES
MAIA INC.
LIN BLUE OWL CAPITAL INC
WEST IMMIX BIOPHARMA INC
SMRT NUVALENT INC
FISV MAIA BIOTECHNOLOGY INC
XELB LINDE PUBLIC LIMITED COMPANY
SI WESTROCK COFFEE COMPANY LLC
ASST SMARTRENT INC
GMRE FISERV
SEVN INC.
MPTI XCEL BRANDS INC.
SHOULDER INNOVATIONS INC
ASSET ENTITIES INC.
GLOBAL MEDICAL REIT INC.
SEVEN HILLS REALTY TRUST
M-TRON INDUSTRIES
INC.
- Jonathan Moreland
AAON AAON INC.
WHF WHITEHORSE FINANCE INC.
SPG SIMON PROPERTY GROUP INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
HNRG HALLADOR ENERGY CO.
GOGO GOGO INC.
CUBE CUBESMART
CLFD CLEARFIELD INC.
AZO AUTOZONE INC.
ASA ASA
NB NIOCORP DEVELOPMENTS LTD
QTA QUATERRA RESOURCES INC.
WVE WAVE LIFE SCIENCES
IGR CBRE CLARION GLOBAL REAL ESTAT
WMG WARNER MUSIC GROUP CORP.
NKE NIKE INC. CLASS B
DIS THE WALT DISNEY COMPANY
ULBI ULTRALIFE
ELAN ELANCO ANIMAL HEALTH INC.
KOD KODIAK SCIENCES
EML THE EASTERN COMPANY
MIDD THE MIDDLEBY CORPORATION
PHR PHREESIA
DHC DIVERSIFIED HEALTHCARE TRUST
ALT ALTIMMUNE INC
COO THE COOPER COMPANIES INC.
RZLT REZOLUTE
AZYO INC.
DLHC AZIYO BIOLOGICS
AMR DALEIGH HOLDINGS CORP
BMEA ALPHA METALLURGICAL RESOURCES INC
WRB BIOMEA FUSION
NUVL INC.
MAIA W.R. BERKLEY CORPORATION
KVUE NUVALENT INC
GTE MAIA BIOTECHNOLOGY INC
NBBK KENVUE INC
SI GRAN TIERRA ENERGY INC.
ASST NB BANCORP INC.
MPTI SHOULDER INNOVATIONS INC
ASSET ENTITIES INC.
M-TRON INDUSTRIES
INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.